Logo image of EQOS

EQONEX LTD (EQOS) Stock Fundamental Analysis

NASDAQ:EQOS - Nasdaq - SGXZ53262598 - Common Stock - Currency: USD

0.0931  -0.05 (-33.88%)

After market: 0.0869 -0.01 (-6.66%)

Fundamental Rating

2

Overall EQOS gets a fundamental rating of 2 out of 10. We evaluated EQOS against 232 industry peers in the Capital Markets industry. EQOS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, EQOS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year EQOS has reported negative net income.
EQOS had a negative operating cash flow in the past year.
EQOS Yearly Net Income VS EBIT VS OCF VS FCFEQOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of EQOS (-122.39%) is worse than 98.06% of its industry peers.
Industry RankSector Rank
ROA -122.39%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EQOS Yearly ROA, ROE, ROICEQOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -500 -1K -1.5K

1.3 Margins

EQOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQOS Yearly Profit, Operating, Gross MarginsEQOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 1K -1K

3

2. Health

2.1 Basic Checks

EQOS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for EQOS is higher compared to a year ago.
EQOS Yearly Shares OutstandingEQOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
EQOS Yearly Total Debt VS Total AssetsEQOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -11.66, we must say that EQOS is in the distress zone and has some risk of bankruptcy.
EQOS's Altman-Z score of -11.66 is fine compared to the rest of the industry. EQOS outperforms 76.21% of its industry peers.
EQOS has a Debt/Equity ratio of 1.65. This is a high value indicating a heavy dependency on external financing.
EQOS has a Debt to Equity ratio of 1.65. This is amonst the worse of the industry: EQOS underperforms 82.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF N/A
Altman-Z -11.66
ROIC/WACCN/A
WACCN/A
EQOS Yearly LT Debt VS Equity VS FCFEQOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.08 indicates that EQOS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.08, EQOS belongs to the top of the industry, outperforming 80.58% of the companies in the same industry.
EQOS has a Quick Ratio of 1.08. This is a normal value and indicates that EQOS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EQOS (1.08) is better than 81.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
EQOS Yearly Current Assets VS Current LiabilitesEQOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 10M 20M 30M 40M 50M

6

3. Growth

3.1 Past

The earnings per share for EQOS have decreased strongly by -1533.22% in the last year.
Looking at the last year, EQOS shows a very strong growth in Revenue. The Revenue has grown by 1741.83%.
The Revenue has been growing by 77.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1533.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3194.97%
Revenue 1Y (TTM)1741.83%
Revenue growth 3Y77.3%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.42% on average over the next years. This is quite good.
Based on estimates for the next years, EQOS will show a very strong growth in Revenue. The Revenue will grow by 52.26% on average per year.
EPS Next Y63.76%
EPS Next 2Y41.05%
EPS Next 3Y25.6%
EPS Next 5Y18.42%
Revenue Next Year-41.3%
Revenue Next 2Y31.89%
Revenue Next 3Y44.66%
Revenue Next 5Y52.26%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EQOS Yearly Revenue VS EstimatesEQOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
EQOS Yearly EPS VS EstimatesEQOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EQOS. In the last year negative earnings were reported.
Also next year EQOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQOS Price Earnings VS Forward Price EarningsEQOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQOS Per share dataEQOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

EQOS's earnings are expected to grow with 25.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.05%
EPS Next 3Y25.6%

0

5. Dividend

5.1 Amount

EQOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EQONEX LTD

NASDAQ:EQOS (11/29/2022, 8:00:01 PM)

After market: 0.0869 -0.01 (-6.66%)

0.0931

-0.05 (-33.88%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)09-06 2022-09-06/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.31M
Analysts45.71
Price Target5.36 (5657.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z -11.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1533.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3194.97%
EPS Next Y63.76%
EPS Next 2Y41.05%
EPS Next 3Y25.6%
EPS Next 5Y18.42%
Revenue 1Y (TTM)1741.83%
Revenue growth 3Y77.3%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-41.3%
Revenue Next 2Y31.89%
Revenue Next 3Y44.66%
Revenue Next 5Y52.26%
EBIT growth 1Y-4878.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.84%
EBIT Next 3Y48.54%
EBIT Next 5Y50.96%
FCF growth 1Y-4716.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3996.89%
OCF growth 3YN/A
OCF growth 5YN/A